Lei Chen

Lei Chen

Auto-generated profile, based on publicly available information

Lei Chen

Department of Endocrinology, Suzhou Municipal Hospital, Suzhou, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2025 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
JCJinghao Cai
Jinghao Cai
JLJiechen Liu
Jiechen Liu
JLJingyi Lu
Jingyi Lu
JNJiaying Ni
Jiaying Ni
CWChunfang Wang
Chunfang Wang
JZJian Zhou
Jian Zhou
Aims: Currently, there is a lack of evidence regarding time in tight range (TITR) and long‐term adverse outcomes. We aimed to investigate the association between TITR and the risk of all‐cause and cardiovascular mortality among patients with type 2 diabetes. Materials and Methods: A total of 6061 patients with type 2 diabetes were prospectively recruited in a single centre. TITR was measured with continuous glucose monitoring (CGM) at baseline and was defined as the percentage of time in the target glucose range of 3.9–7.8 mmol/L (70–140 mg/dL) during a 24‐h period. Cox proportion hazard regression models were used to examine the association between TITR and the risk of all‐cause and cardiovascular mortality. Results: During a median follow‐up period of 10.9 years, 1898 (31.3%) death events were confirmed, with 689 (11.4%) due to cardiovascular mortality. The restricted cubic spline revealed significant linear relationships between lower TITR and higher risks of all‐cause and cardiovascular mortality ( p for linearity <0.01). In the fully adjusted model including glycated haemoglobin A1c, each 10% decrease in TITR was associated with 4% (95% confidence interval, 1.01–1.06) increased risk of all‐cause mortality and 4% (95% confidence interval, 1.00–1.08) increased risk of cardiovascular mortality. Subgroup analyses showed that the linear relationship between TITR and all‐cause mortality risk was sustained in patients with haemoglobin A1c <7.0% and patients with fasting plasma glucose <7.0 mmol/L. Conclusions: Lower TITR is associated with an increased risk of all‐cause and cardiovascular mortality in patients with type 2 diabetes, indicating that tight glycaemic control within the physiological range may be crucial for reducing long‐term mortality risk, especially in those with seemingly well‐controlled diabetes.

9 March 2021 in Diabetologia
Verified
Journal Article
Open access
PDF file
LJLinong Ji
Linong Ji
YDYing Du
Ying Du
MXMin Xu
Min Xu
XZXiangjun Zhou
Xiangjun Zhou
ZMZhaohui Mo
Zhaohui Mo
LCLei Chen
Lei Chen
Aims/hypothesis: Glucagon-like peptide 1 receptor agonists (GLP-1 RA) such as exenatide are used as monotherapy and add-on therapy for maintaining glycaemic control in patients with type 2 diabetes mellitus. The current study investigated the safety and efficacy of once-weekly PB-119, a PEGylated exenatide injection, in treatment-naive patients with type 2 diabetes. Methods: In this Phase II, randomised, placebo-controlled, double-blind study, we randomly assigned treatment-naive Chinese patients with type 2 diabetes in a 1:1:1:1 ratio to receive subcutaneous placebo or one of three subcutaneous doses of PB-119 (75, 150, and 200 μg) for 12 weeks. The primary endpoint was the change in HbA1c from baseline to week 12, and other endpoints were fasting plasma glucose, 2 h postprandial glucose (PPG), and proportion of patients with HbA1c < 53 mmol/mol (<7.0%) and ≤48 mmol/mol (≤6.5%) at 2, 4, 8 and 12 weeks of treatment. Safety was assessed in all patients who received at least one dose of study drug. Results: We randomly assigned 251 patients to one of the four treatment groups (n = 62 in placebo and 63 each in PB-119 75 μg, 150 μg and 200 μg groups). At the end of 12 weeks, mean differences in HbA1c in the treatment groups were −7.76 mmol/mol (95% CI −9.23, −4.63, p < 0.001) (−0.72%, 95% CI −1.01, −0.43), −12.89 mmol/mol (95% CI −16.05, −9.72, p < 0.001) (−1.18%, 95% CI −1.47, −0.89) and −11.14 mmol/mol (95% CI −14.19, −7.97, p <0 .001) (−1.02%, 95% CI −1.30, −0.73) in the 75 μg, 150 μg and 200 μg PB-119 groups, respectively, compared with that in the placebo group after adjusting for baseline HbA1c. Similar results were also observed for other efficacy endpoints across different time points. There was no incidence of treatment-emergent serious adverse event, severe hypoglycaemia or death. Conclusions/interpretation: All tested PB-119 doses had superior efficacy compared with placebo and were safe and well tolerated over 12 weeks in treatment-naive Chinese patients with type 2 diabetes. Trial registration: ClinicalTrials.gov NCT03520972 Funding: The study was funded by National Major Scientific and Technological Special Project for Significant New Drugs Development and PegBio. Graphical

26 May 2021 in Diabetologia
Verified
Journal Article
Open access
PDF file
LJLinong Ji
Linong Ji
YDYing Du
Ying Du
MXMin Xu
Min Xu
XZXiangjun Zhou
Xiangjun Zhou
ZMZhaohui Mo
Zhaohui Mo
LCLei Chen
Lei Chen
A Correction to this paper has been published: 10.1007/s00125-021-05460-0